ArticleBritish journal of haematology2019

Combination lenalidomide-rituximab immunotherapy activates anti-tumour immunity and induces tumour cell death by complementary mechanisms of action in follicular lymphoma.

Hsiling Chiu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.